Loading
NKT2152 is an experimental pill from NiKang Therapeutics, in phase 2 trials for clear cell renal cell carcinoma.
NKT2152 is a small molecule, oral from NiKang Therapeutics. An allosteric inhibitor of HIF-2α (HIF2-alpha) that breaks up the HIF2-alpha and HIF1-beta complex. Both NiKang-sponsored studies in clear cell renal cell carcinoma (NCT05119335 and NCT05935748, the second with palbociclib and sasanlimab) are terminated; the sources read do not say whether kidney cancer development continues. It is also one of the drugs in Roche's MORPHEUS-Liver platform study in liver cancer.
An allosteric inhibitor of HIF-2α (HIF2-alpha) that breaks up the HIF2-alpha and HIF1-beta complex. Connects to HIF-2α.
1.NKT2152 slips into a pocket on HIF-2α.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"NKT2152" OR ABSTRACT:"NKT2152") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NKT2152, not a curated reading list.
Shares NiKang Therapeutics and the tag pipeline.
Shares NiKang Therapeutics and the tag pipeline.
Shares NiKang Therapeutics and the tag pipeline.
Shares NiKang Therapeutics and the tag pipeline.
Shares Clear cell renal cell carcinoma and the tag pipeline.
Shares Clear cell renal cell carcinoma and the tag pipeline.
Shares Clear cell renal cell carcinoma and the tag pipeline.
Shares Clear cell renal cell carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/